nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ALB—Crohn's disease	0.476	1	CbGaD
Vemurafenib—ABCG2—Sulfasalazine—Crohn's disease	0.109	0.58	CbGbCtD
Vemurafenib—ALB—Prednisone—Crohn's disease	0.06	0.32	CbGbCtD
Vemurafenib—CYP3A4—Prednisone—Crohn's disease	0.0188	0.1	CbGbCtD
Vemurafenib—ORM1—bile—Crohn's disease	0.0127	0.297	CbGeAlD
Vemurafenib—Malignant melanoma—Azathioprine—Crohn's disease	0.00704	0.0528	CcSEcCtD
Vemurafenib—Uveitis—Azathioprine—Crohn's disease	0.00526	0.0395	CcSEcCtD
Vemurafenib—Polyp—Mercaptopurine—Crohn's disease	0.00507	0.038	CcSEcCtD
Vemurafenib—Cyst—Mercaptopurine—Crohn's disease	0.00461	0.0346	CcSEcCtD
Vemurafenib—Hepatotoxicity—Mercaptopurine—Crohn's disease	0.00399	0.03	CcSEcCtD
Vemurafenib—Rash generalised—Mesalazine—Crohn's disease	0.00394	0.0295	CcSEcCtD
Vemurafenib—Erythema nodosum—Mesalazine—Crohn's disease	0.00387	0.029	CcSEcCtD
Vemurafenib—ORM1—gall bladder—Crohn's disease	0.00352	0.0824	CbGeAlD
Vemurafenib—ALB—gall bladder—Crohn's disease	0.00308	0.0722	CbGeAlD
Vemurafenib—Polyp—Azathioprine—Crohn's disease	0.00302	0.0227	CcSEcCtD
Vemurafenib—Neoplasm—Mercaptopurine—Crohn's disease	0.00279	0.0209	CcSEcCtD
Vemurafenib—Cyst—Azathioprine—Crohn's disease	0.00275	0.0206	CcSEcCtD
Vemurafenib—RAF1—epithelium—Crohn's disease	0.00264	0.0617	CbGeAlD
Vemurafenib—RAF1—smooth muscle tissue—Crohn's disease	0.00254	0.0595	CbGeAlD
Vemurafenib—RAF1—skin of body—Crohn's disease	0.00251	0.0587	CbGeAlD
Vemurafenib—Hepatotoxicity—Azathioprine—Crohn's disease	0.00238	0.0179	CcSEcCtD
Vemurafenib—Etoricoxib—PTGS2—Crohn's disease	0.00236	1	CrCbGaD
Vemurafenib—RAF1—mammalian vulva—Crohn's disease	0.00229	0.0535	CbGeAlD
Vemurafenib—Rigors—Azathioprine—Crohn's disease	0.00225	0.0169	CcSEcCtD
Vemurafenib—Hepatotoxicity—Mesalazine—Crohn's disease	0.00217	0.0163	CcSEcCtD
Vemurafenib—Neoplasm malignant—Azathioprine—Crohn's disease	0.00215	0.0161	CcSEcCtD
Vemurafenib—Gamma-glutamyltransferase increased—Mesalazine—Crohn's disease	0.00203	0.0153	CcSEcCtD
Vemurafenib—RAF1—lymphoid tissue—Crohn's disease	0.00203	0.0475	CbGeAlD
Vemurafenib—RAF1—digestive system—Crohn's disease	0.00201	0.047	CbGeAlD
Vemurafenib—Vasculitis—Azathioprine—Crohn's disease	0.00188	0.0141	CcSEcCtD
Vemurafenib—BRAF—lymph node—Crohn's disease	0.00172	0.0403	CbGeAlD
Vemurafenib—Musculoskeletal pain—Mesalazine—Crohn's disease	0.00169	0.0127	CcSEcCtD
Vemurafenib—Neoplasm—Azathioprine—Crohn's disease	0.00166	0.0125	CcSEcCtD
Vemurafenib—Photosensitivity—Mesalazine—Crohn's disease	0.00138	0.0104	CcSEcCtD
Vemurafenib—Alopecia—Mercaptopurine—Crohn's disease	0.00137	0.0103	CcSEcCtD
Vemurafenib—Malnutrition—Mercaptopurine—Crohn's disease	0.00135	0.0101	CcSEcCtD
Vemurafenib—Atrial fibrillation—Mesalazine—Crohn's disease	0.00128	0.00962	CcSEcCtD
Vemurafenib—Arthritis—Mesalazine—Crohn's disease	0.00125	0.00938	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.0012	0.00901	CcSEcCtD
Vemurafenib—Arthralgia—Mercaptopurine—Crohn's disease	0.00115	0.00861	CcSEcCtD
Vemurafenib—RAF1—lymph node—Crohn's disease	0.00115	0.0268	CbGeAlD
Vemurafenib—ABCC1—mammalian vulva—Crohn's disease	0.00114	0.0268	CbGeAlD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00114	0.00855	CcSEcCtD
Vemurafenib—Dry skin—Mesalazine—Crohn's disease	0.00111	0.00835	CcSEcCtD
Vemurafenib—Skin disorder—Mercaptopurine—Crohn's disease	0.00107	0.00802	CcSEcCtD
Vemurafenib—Eosinophilia—Mesalazine—Crohn's disease	0.00104	0.0078	CcSEcCtD
Vemurafenib—Infestation—Azathioprine—Crohn's disease	0.00103	0.00771	CcSEcCtD
Vemurafenib—Infestation NOS—Azathioprine—Crohn's disease	0.00103	0.00771	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.00102	0.00764	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.001	0.00752	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Mesalazine—Crohn's disease	0.000959	0.00719	CcSEcCtD
Vemurafenib—Decreased appetite—Mercaptopurine—Crohn's disease	0.000957	0.00718	CcSEcCtD
Vemurafenib—Weight decreased—Mesalazine—Crohn's disease	0.00095	0.00713	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00095	0.00713	CcSEcCtD
Vemurafenib—ABCG2—mammalian vulva—Crohn's disease	0.000946	0.0221	CbGeAlD
Vemurafenib—Infestation NOS—Mesalazine—Crohn's disease	0.000936	0.00702	CcSEcCtD
Vemurafenib—Infestation—Mesalazine—Crohn's disease	0.000936	0.00702	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.000928	0.00696	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000918	0.00688	CcSEcCtD
Vemurafenib—Vasculitis—Prednisone—Crohn's disease	0.000907	0.00681	CcSEcCtD
Vemurafenib—Erythema multiforme—Azathioprine—Crohn's disease	0.000873	0.00655	CcSEcCtD
Vemurafenib—Body temperature increased—Mercaptopurine—Crohn's disease	0.00087	0.00652	CcSEcCtD
Vemurafenib—Mediastinal disorder—Azathioprine—Crohn's disease	0.000832	0.00624	CcSEcCtD
Vemurafenib—Oedema peripheral—Mesalazine—Crohn's disease	0.000828	0.00621	CcSEcCtD
Vemurafenib—Chills—Azathioprine—Crohn's disease	0.000828	0.00621	CcSEcCtD
Vemurafenib—Connective tissue disorder—Mesalazine—Crohn's disease	0.000826	0.0062	CcSEcCtD
Vemurafenib—Alopecia—Azathioprine—Crohn's disease	0.000815	0.00612	CcSEcCtD
Vemurafenib—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000811	0.00608	CcSEcCtD
Vemurafenib—CYP1A2—digestive system—Crohn's disease	0.000798	0.0187	CbGeAlD
Vemurafenib—Erythema multiforme—Mesalazine—Crohn's disease	0.000795	0.00596	CcSEcCtD
Vemurafenib—ORM1—lymph node—Crohn's disease	0.000791	0.0185	CbGeAlD
Vemurafenib—Eye disorder—Mesalazine—Crohn's disease	0.000786	0.00589	CcSEcCtD
Vemurafenib—Cardiac disorder—Mesalazine—Crohn's disease	0.00078	0.00585	CcSEcCtD
Vemurafenib—Angiopathy—Mesalazine—Crohn's disease	0.000763	0.00572	CcSEcCtD
Vemurafenib—Mediastinal disorder—Mesalazine—Crohn's disease	0.000758	0.00568	CcSEcCtD
Vemurafenib—Chills—Mesalazine—Crohn's disease	0.000754	0.00566	CcSEcCtD
Vemurafenib—Diarrhoea—Mercaptopurine—Crohn's disease	0.000753	0.00565	CcSEcCtD
Vemurafenib—Alopecia—Mesalazine—Crohn's disease	0.000743	0.00557	CcSEcCtD
Vemurafenib—Erythema—Mesalazine—Crohn's disease	0.000732	0.00549	CcSEcCtD
Vemurafenib—Dysgeusia—Mesalazine—Crohn's disease	0.000717	0.00538	CcSEcCtD
Vemurafenib—Back pain—Mesalazine—Crohn's disease	0.000708	0.00531	CcSEcCtD
Vemurafenib—Vomiting—Mercaptopurine—Crohn's disease	0.0007	0.00525	CcSEcCtD
Vemurafenib—Rash—Mercaptopurine—Crohn's disease	0.000694	0.0052	CcSEcCtD
Vemurafenib—ALB—lymph node—Crohn's disease	0.000693	0.0162	CbGeAlD
Vemurafenib—Dermatitis—Mercaptopurine—Crohn's disease	0.000693	0.0052	CcSEcCtD
Vemurafenib—Myalgia—Azathioprine—Crohn's disease	0.000684	0.00513	CcSEcCtD
Vemurafenib—Arthralgia—Azathioprine—Crohn's disease	0.000684	0.00513	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000679	0.00509	CcSEcCtD
Vemurafenib—Nausea—Mercaptopurine—Crohn's disease	0.000654	0.0049	CcSEcCtD
Vemurafenib—Infection—Azathioprine—Crohn's disease	0.000651	0.00489	CcSEcCtD
Vemurafenib—Cough—Mesalazine—Crohn's disease	0.000639	0.00479	CcSEcCtD
Vemurafenib—Skin disorder—Azathioprine—Crohn's disease	0.000637	0.00478	CcSEcCtD
Vemurafenib—Arthralgia—Mesalazine—Crohn's disease	0.000623	0.00467	CcSEcCtD
Vemurafenib—Myalgia—Mesalazine—Crohn's disease	0.000623	0.00467	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000619	0.00464	CcSEcCtD
Vemurafenib—Hypotension—Azathioprine—Crohn's disease	0.000613	0.0046	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000597	0.00448	CcSEcCtD
Vemurafenib—Anaphylactic shock—Mesalazine—Crohn's disease	0.000597	0.00448	CcSEcCtD
Vemurafenib—Infection—Mesalazine—Crohn's disease	0.000593	0.00445	CcSEcCtD
Vemurafenib—Dry skin—Prednisone—Crohn's disease	0.000589	0.00442	CcSEcCtD
Vemurafenib—Nervous system disorder—Mesalazine—Crohn's disease	0.000586	0.00439	CcSEcCtD
Vemurafenib—Skin disorder—Mesalazine—Crohn's disease	0.00058	0.00435	CcSEcCtD
Vemurafenib—CYP3A4—digestive system—Crohn's disease	0.000578	0.0135	CbGeAlD
Vemurafenib—ABCC1—lymph node—Crohn's disease	0.000572	0.0134	CbGeAlD
Vemurafenib—CYP2D6—digestive system—Crohn's disease	0.000569	0.0133	CbGeAlD
Vemurafenib—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000566	0.00425	CcSEcCtD
Vemurafenib—Hypotension—Mesalazine—Crohn's disease	0.000558	0.00419	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000544	0.00408	CcSEcCtD
Vemurafenib—Decreased appetite—Mesalazine—Crohn's disease	0.000519	0.00389	CcSEcCtD
Vemurafenib—Body temperature increased—Azathioprine—Crohn's disease	0.000518	0.00389	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000516	0.00387	CcSEcCtD
Vemurafenib—Fatigue—Mesalazine—Crohn's disease	0.000515	0.00386	CcSEcCtD
Vemurafenib—Constipation—Mesalazine—Crohn's disease	0.000511	0.00383	CcSEcCtD
Vemurafenib—Weight decreased—Prednisone—Crohn's disease	0.000503	0.00377	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Prednisone—Crohn's disease	0.000486	0.00364	CcSEcCtD
Vemurafenib—Hypersensitivity—Azathioprine—Crohn's disease	0.000483	0.00362	CcSEcCtD
Vemurafenib—ABCG2—lymph node—Crohn's disease	0.000474	0.0111	CbGeAlD
Vemurafenib—Body temperature increased—Mesalazine—Crohn's disease	0.000472	0.00354	CcSEcCtD
Vemurafenib—Diarrhoea—Azathioprine—Crohn's disease	0.000449	0.00336	CcSEcCtD
Vemurafenib—Hypersensitivity—Mesalazine—Crohn's disease	0.00044	0.0033	CcSEcCtD
Vemurafenib—Connective tissue disorder—Prednisone—Crohn's disease	0.000437	0.00328	CcSEcCtD
Vemurafenib—Dizziness—Azathioprine—Crohn's disease	0.000434	0.00325	CcSEcCtD
Vemurafenib—Asthenia—Mesalazine—Crohn's disease	0.000428	0.00321	CcSEcCtD
Vemurafenib—Pruritus—Mesalazine—Crohn's disease	0.000423	0.00317	CcSEcCtD
Vemurafenib—Vomiting—Azathioprine—Crohn's disease	0.000417	0.00313	CcSEcCtD
Vemurafenib—Eye disorder—Prednisone—Crohn's disease	0.000416	0.00312	CcSEcCtD
Vemurafenib—Rash—Azathioprine—Crohn's disease	0.000413	0.0031	CcSEcCtD
Vemurafenib—Dermatitis—Azathioprine—Crohn's disease	0.000413	0.0031	CcSEcCtD
Vemurafenib—Headache—Azathioprine—Crohn's disease	0.000411	0.00308	CcSEcCtD
Vemurafenib—Diarrhoea—Mesalazine—Crohn's disease	0.000409	0.00307	CcSEcCtD
Vemurafenib—Angiopathy—Prednisone—Crohn's disease	0.000404	0.00303	CcSEcCtD
Vemurafenib—Dizziness—Mesalazine—Crohn's disease	0.000395	0.00296	CcSEcCtD
Vemurafenib—Alopecia—Prednisone—Crohn's disease	0.000393	0.00295	CcSEcCtD
Vemurafenib—Nausea—Azathioprine—Crohn's disease	0.000389	0.00292	CcSEcCtD
Vemurafenib—Erythema—Prednisone—Crohn's disease	0.000387	0.0029	CcSEcCtD
Vemurafenib—Malnutrition—Prednisone—Crohn's disease	0.000387	0.0029	CcSEcCtD
Vemurafenib—Vomiting—Mesalazine—Crohn's disease	0.00038	0.00285	CcSEcCtD
Vemurafenib—Rash—Mesalazine—Crohn's disease	0.000377	0.00282	CcSEcCtD
Vemurafenib—Dermatitis—Mesalazine—Crohn's disease	0.000376	0.00282	CcSEcCtD
Vemurafenib—Headache—Mesalazine—Crohn's disease	0.000374	0.00281	CcSEcCtD
Vemurafenib—Nausea—Mesalazine—Crohn's disease	0.000355	0.00266	CcSEcCtD
Vemurafenib—Myalgia—Prednisone—Crohn's disease	0.00033	0.00247	CcSEcCtD
Vemurafenib—Arthralgia—Prednisone—Crohn's disease	0.00033	0.00247	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000327	0.00246	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisone—Crohn's disease	0.000316	0.00237	CcSEcCtD
Vemurafenib—Infection—Prednisone—Crohn's disease	0.000314	0.00235	CcSEcCtD
Vemurafenib—Nervous system disorder—Prednisone—Crohn's disease	0.00031	0.00232	CcSEcCtD
Vemurafenib—Skin disorder—Prednisone—Crohn's disease	0.000307	0.0023	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000288	0.00216	CcSEcCtD
Vemurafenib—Decreased appetite—Prednisone—Crohn's disease	0.000275	0.00206	CcSEcCtD
Vemurafenib—Fatigue—Prednisone—Crohn's disease	0.000272	0.00204	CcSEcCtD
Vemurafenib—Constipation—Prednisone—Crohn's disease	0.00027	0.00203	CcSEcCtD
Vemurafenib—Body temperature increased—Prednisone—Crohn's disease	0.00025	0.00187	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisone—Crohn's disease	0.000233	0.00175	CcSEcCtD
Vemurafenib—Asthenia—Prednisone—Crohn's disease	0.000227	0.0017	CcSEcCtD
Vemurafenib—Pruritus—Prednisone—Crohn's disease	0.000224	0.00168	CcSEcCtD
Vemurafenib—Diarrhoea—Prednisone—Crohn's disease	0.000216	0.00162	CcSEcCtD
Vemurafenib—Dizziness—Prednisone—Crohn's disease	0.000209	0.00157	CcSEcCtD
Vemurafenib—Vomiting—Prednisone—Crohn's disease	0.000201	0.00151	CcSEcCtD
Vemurafenib—Rash—Prednisone—Crohn's disease	0.000199	0.00149	CcSEcCtD
Vemurafenib—Dermatitis—Prednisone—Crohn's disease	0.000199	0.00149	CcSEcCtD
Vemurafenib—Headache—Prednisone—Crohn's disease	0.000198	0.00148	CcSEcCtD
Vemurafenib—Nausea—Prednisone—Crohn's disease	0.000188	0.00141	CcSEcCtD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	9.4e-05	0.000595	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—RIPK2—Crohn's disease	9.3e-05	0.000588	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GPR65—Crohn's disease	9.23e-05	0.000584	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—UBE2D1—Crohn's disease	9.2e-05	0.000582	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	9.2e-05	0.000582	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	9.17e-05	0.00058	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—MTMR3—Crohn's disease	9.14e-05	0.000578	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TAGAP—Crohn's disease	9.07e-05	0.000573	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL1B—Crohn's disease	9.05e-05	0.000573	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—F5—Crohn's disease	9.04e-05	0.000572	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ITGA4—Crohn's disease	8.93e-05	0.000565	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—RIPK2—Crohn's disease	8.93e-05	0.000565	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—RASGRP1—Crohn's disease	8.77e-05	0.000555	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR—IL6—Crohn's disease	8.74e-05	0.000553	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—STAT3—Crohn's disease	8.7e-05	0.00055	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	8.68e-05	0.000549	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—STAT3—Crohn's disease	8.65e-05	0.000547	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—TAB1—Crohn's disease	8.58e-05	0.000543	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—IL6—Crohn's disease	8.55e-05	0.000541	CbGpPWpGaD
Vemurafenib—BRAF—Disease—RBX1—Crohn's disease	8.5e-05	0.000537	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HSPA1B—Crohn's disease	8.5e-05	0.000537	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—NOD2—Crohn's disease	8.43e-05	0.000533	CbGpPWpGaD
Vemurafenib—RAF1—VEGFA-VEGFR2 Pathway—IL6—Crohn's disease	8.42e-05	0.000533	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—RASGRP1—Crohn's disease	8.42e-05	0.000532	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD79A—Crohn's disease	8.39e-05	0.000531	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—IL6—Crohn's disease	8.36e-05	0.000529	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TNF—Crohn's disease	8.27e-05	0.000523	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—IL6—Crohn's disease	8.2e-05	0.000519	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—IL6—Crohn's disease	8.14e-05	0.000515	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	8.13e-05	0.000514	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—STAT3—Crohn's disease	8.06e-05	0.00051	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—MTMR3—Crohn's disease	8.04e-05	0.000509	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—TYK2—Crohn's disease	7.98e-05	0.000505	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by VEGF—IL6—Crohn's disease	7.95e-05	0.000503	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—SOCS1—Crohn's disease	7.94e-05	0.000502	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—STAT3—Crohn's disease	7.94e-05	0.000502	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RSPO3—Crohn's disease	7.93e-05	0.000501	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Insulin receptor—IL6—Crohn's disease	7.9e-05	0.000499	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—STAT3—Crohn's disease	7.88e-05	0.000499	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—TYK2—Crohn's disease	7.84e-05	0.000496	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	7.79e-05	0.000493	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—SMAD3—Crohn's disease	7.76e-05	0.000491	CbGpPWpGaD
Vemurafenib—RAF1—Disease—GCKR—Crohn's disease	7.76e-05	0.000491	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NOD1—Crohn's disease	7.75e-05	0.00049	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	7.72e-05	0.000488	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	7.72e-05	0.000488	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCR6—Crohn's disease	7.71e-05	0.000487	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—GCKR—Crohn's disease	7.69e-05	0.000486	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—SOCS1—Crohn's disease	7.63e-05	0.000482	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—JAK2—Crohn's disease	7.61e-05	0.000481	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SEL1L—Crohn's disease	7.51e-05	0.000475	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—JAK2—Crohn's disease	7.48e-05	0.000473	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IFNG—Crohn's disease	7.47e-05	0.000472	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—GCKR—Crohn's disease	7.46e-05	0.000472	CbGpPWpGaD
Vemurafenib—BRAF—Disease—UBE2D1—Crohn's disease	7.45e-05	0.000471	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—IL2RA—Crohn's disease	7.36e-05	0.000466	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TNF—Crohn's disease	7.28e-05	0.00046	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	7.21e-05	0.000456	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—STAT3—Crohn's disease	7.14e-05	0.000452	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—FADS1—Crohn's disease	7.12e-05	0.00045	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—TYK2—Crohn's disease	7.1e-05	0.000449	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IL2RA—Crohn's disease	7.05e-05	0.000446	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CCR6—Crohn's disease	7.04e-05	0.000445	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCR9—Crohn's disease	6.87e-05	0.000435	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SLC11A1—Crohn's disease	6.86e-05	0.000434	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SLC11A1—Crohn's disease	6.8e-05	0.00043	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PTGER4—Crohn's disease	6.78e-05	0.000429	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—JAK2—Crohn's disease	6.77e-05	0.000428	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—IL6—Crohn's disease	6.75e-05	0.000427	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IL6—Crohn's disease	6.67e-05	0.000422	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GPX4—Crohn's disease	6.67e-05	0.000422	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL1B—Crohn's disease	6.66e-05	0.000421	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	6.6e-05	0.000417	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCR6—Crohn's disease	6.58e-05	0.000416	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—TNF—Crohn's disease	6.57e-05	0.000415	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	6.57e-05	0.000415	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—IL6—Crohn's disease	6.46e-05	0.000409	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GCKR—Crohn's disease	6.44e-05	0.000407	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PTPN2—Crohn's disease	6.44e-05	0.000407	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GPR65—Crohn's disease	6.39e-05	0.000404	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—RBX1—Crohn's disease	6.37e-05	0.000403	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—IL6—Crohn's disease	6.36e-05	0.000402	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—FADS1—Crohn's disease	6.27e-05	0.000396	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—IL6—Crohn's disease	6.07e-05	0.000384	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	6.07e-05	0.000384	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—IL6—Crohn's disease	6.04e-05	0.000382	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—IL6—Crohn's disease	6.02e-05	0.00038	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CRP—Crohn's disease	5.99e-05	0.000379	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—IL6—Crohn's disease	5.99e-05	0.000379	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RBX1—Crohn's disease	5.95e-05	0.000376	CbGpPWpGaD
Vemurafenib—RAF1—Disease—RBX1—Crohn's disease	5.88e-05	0.000372	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HSPA1B—Crohn's disease	5.88e-05	0.000372	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GPX4—Crohn's disease	5.87e-05	0.000371	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PLA2G4F—Crohn's disease	5.84e-05	0.000369	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HSPA1B—Crohn's disease	5.83e-05	0.000369	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—RBX1—Crohn's disease	5.83e-05	0.000369	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTGER4—Crohn's disease	5.79e-05	0.000366	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL3—Crohn's disease	5.78e-05	0.000365	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—TLR4—Crohn's disease	5.74e-05	0.000363	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	5.69e-05	0.00036	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GCKR—Crohn's disease	5.67e-05	0.000358	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—IL6—Crohn's disease	5.63e-05	0.000356	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—Crohn's disease	5.63e-05	0.000356	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—IL6—Crohn's disease	5.63e-05	0.000356	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—RASGRP1—Crohn's disease	5.59e-05	0.000353	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—STAT3—Crohn's disease	5.59e-05	0.000353	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—UBE2D1—Crohn's disease	5.58e-05	0.000353	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—IL6—Crohn's disease	5.58e-05	0.000353	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—ITGA4—Crohn's disease	5.56e-05	0.000351	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—IL6—Crohn's disease	5.54e-05	0.000351	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—IL6—Crohn's disease	5.53e-05	0.00035	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—IL6—Crohn's disease	5.51e-05	0.000348	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—STAT3—Crohn's disease	5.49e-05	0.000347	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL3—Crohn's disease	5.42e-05	0.000343	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—RIPK2—Crohn's disease	5.41e-05	0.000342	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ITGA4—Crohn's disease	5.41e-05	0.000342	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SMAD3—Crohn's disease	5.33e-05	0.000337	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL6—Crohn's disease	5.3e-05	0.000335	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ICAM1—Crohn's disease	5.29e-05	0.000334	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL3—Crohn's disease	5.28e-05	0.000334	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—RASGRP1—Crohn's disease	5.24e-05	0.000332	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—UBE2D1—Crohn's disease	5.22e-05	0.00033	CbGpPWpGaD
Vemurafenib—RAF1—Disease—UBE2D1—Crohn's disease	5.15e-05	0.000326	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—UBE2D1—Crohn's disease	5.11e-05	0.000323	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—RASGRP1—Crohn's disease	5.11e-05	0.000323	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—ALB—Crohn's disease	5.1e-05	0.000323	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD79A—Crohn's disease	5.09e-05	0.000322	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TYK2—Crohn's disease	5.07e-05	0.00032	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RIPK2—Crohn's disease	5.06e-05	0.00032	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TAB1—Crohn's disease	5e-05	0.000316	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	4.99e-05	0.000315	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—MTMR3—Crohn's disease	4.96e-05	0.000314	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	4.95e-05	0.000313	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL3—Crohn's disease	4.93e-05	0.000312	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NOD2—Crohn's disease	4.91e-05	0.00031	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—JAK2—Crohn's disease	4.83e-05	0.000306	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	4.82e-05	0.000305	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PLA2G4F—Crohn's disease	4.82e-05	0.000305	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RASGRP1—Crohn's disease	4.77e-05	0.000302	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—JAK2—Crohn's disease	4.74e-05	0.0003	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SOCS1—Crohn's disease	4.63e-05	0.000293	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	4.6e-05	0.000291	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCR6—Crohn's disease	4.55e-05	0.000288	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—TYK2—Crohn's disease	4.47e-05	0.000283	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—ALB—Crohn's disease	4.41e-05	0.000279	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—ALB—Crohn's disease	4.38e-05	0.000277	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SOCS1—Crohn's disease	4.32e-05	0.000273	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—JAK2—Crohn's disease	4.27e-05	0.00027	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL18—Crohn's disease	4.17e-05	0.000263	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RBX1—Crohn's disease	4.12e-05	0.00026	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—MTMR3—Crohn's disease	4.1e-05	0.000259	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	4.08e-05	0.000258	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2RA—Crohn's disease	4.05e-05	0.000256	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD4—Crohn's disease	4.05e-05	0.000256	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	4.03e-05	0.000255	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTGER4—Crohn's disease	4.01e-05	0.000253	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL6—Crohn's disease	3.9e-05	0.000247	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD4—Crohn's disease	3.89e-05	0.000246	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—FADS1—Crohn's disease	3.87e-05	0.000245	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—ALB—Crohn's disease	3.85e-05	0.000244	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—IL6—Crohn's disease	3.84e-05	0.000243	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2RA—Crohn's disease	3.8e-05	0.00024	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SMAD3—Crohn's disease	3.73e-05	0.000236	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2RA—Crohn's disease	3.7e-05	0.000234	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SMAD3—Crohn's disease	3.69e-05	0.000233	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SMAD3—Crohn's disease	3.66e-05	0.000231	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPX4—Crohn's disease	3.62e-05	0.000229	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—UBE2D1—Crohn's disease	3.61e-05	0.000228	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—STAT3—Crohn's disease	3.55e-05	0.000224	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RIPK2—Crohn's disease	3.5e-05	0.000221	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GCKR—Crohn's disease	3.5e-05	0.000221	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CRP—Crohn's disease	3.49e-05	0.000221	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TYK2—Crohn's disease	3.48e-05	0.00022	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—IL6—Crohn's disease	3.47e-05	0.00022	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—MTMR3—Crohn's disease	3.47e-05	0.00022	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2RA—Crohn's disease	3.46e-05	0.000219	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL3—Crohn's disease	3.41e-05	0.000216	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TLR4—Crohn's disease	3.34e-05	0.000212	CbGpPWpGaD
Vemurafenib—BRAF—Disease—JAK2—Crohn's disease	3.32e-05	0.00021	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RASGRP1—Crohn's disease	3.3e-05	0.000209	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ICAM1—Crohn's disease	3.21e-05	0.000203	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—FADS1—Crohn's disease	3.19e-05	0.000202	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	3.15e-05	0.000199	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD4—Crohn's disease	3.14e-05	0.000199	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—Crohn's disease	3.12e-05	0.000197	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—Crohn's disease	3.07e-05	0.000194	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SOCS1—Crohn's disease	2.99e-05	0.000189	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPX4—Crohn's disease	2.99e-05	0.000189	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GCKR—Crohn's disease	2.89e-05	0.000183	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—TYK2—Crohn's disease	2.85e-05	0.00018	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—JAK2—Crohn's disease	2.72e-05	0.000172	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—FADS1—Crohn's disease	2.7e-05	0.000171	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—MTMR3—Crohn's disease	2.68e-05	0.000169	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TYK2—Crohn's disease	2.61e-05	0.000165	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SMAD3—Crohn's disease	2.58e-05	0.000163	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—JAK2—Crohn's disease	2.55e-05	0.000161	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPX4—Crohn's disease	2.53e-05	0.00016	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—JAK2—Crohn's disease	2.49e-05	0.000157	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL8—Crohn's disease	2.48e-05	0.000157	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—Crohn's disease	2.48e-05	0.000157	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GCKR—Crohn's disease	2.45e-05	0.000155	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNG—Crohn's disease	2.44e-05	0.000154	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TYK2—Crohn's disease	2.44e-05	0.000154	CbGpPWpGaD
Vemurafenib—BRAF—Disease—STAT3—Crohn's disease	2.43e-05	0.000154	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TYK2—Crohn's disease	2.41e-05	0.000152	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2RA—Crohn's disease	2.39e-05	0.000151	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TYK2—Crohn's disease	2.38e-05	0.000151	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD4—Crohn's disease	2.36e-05	0.000149	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—JAK2—Crohn's disease	2.32e-05	0.000147	CbGpPWpGaD
Vemurafenib—RAF1—Disease—JAK2—Crohn's disease	2.3e-05	0.000145	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—JAK2—Crohn's disease	2.27e-05	0.000144	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—Crohn's disease	2.19e-05	0.000138	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	2.19e-05	0.000138	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—Crohn's disease	2.18e-05	0.000138	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD4—Crohn's disease	2.18e-05	0.000138	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—Crohn's disease	2.16e-05	0.000137	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD4—Crohn's disease	2.16e-05	0.000136	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—Crohn's disease	2.14e-05	0.000135	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL8—Crohn's disease	2.12e-05	0.000134	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—FADS1—Crohn's disease	2.09e-05	0.000132	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—Crohn's disease	2.05e-05	0.00013	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX4—Crohn's disease	1.95e-05	0.000124	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GCKR—Crohn's disease	1.89e-05	0.000119	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—Crohn's disease	1.82e-05	0.000115	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—Crohn's disease	1.8e-05	0.000114	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—Crohn's disease	1.79e-05	0.000113	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.75e-05	0.000111	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—Crohn's disease	1.7e-05	0.000108	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—Crohn's disease	1.7e-05	0.000108	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TYK2—Crohn's disease	1.68e-05	0.000107	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—Crohn's disease	1.68e-05	0.000107	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—Crohn's disease	1.67e-05	0.000106	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JAK2—Crohn's disease	1.61e-05	0.000102	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—Crohn's disease	1.58e-05	9.98e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.53e-05	9.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—Crohn's disease	1.47e-05	9.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—Crohn's disease	1.39e-05	8.82e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—Crohn's disease	1.27e-05	8.06e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—Crohn's disease	1.19e-05	7.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—Crohn's disease	1.18e-05	7.46e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—Crohn's disease	1.18e-05	7.44e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—Crohn's disease	1.17e-05	7.38e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—Crohn's disease	9.73e-06	6.16e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—Crohn's disease	9.19e-06	5.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—Crohn's disease	8.24e-06	5.21e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—Crohn's disease	8.04e-06	5.08e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—Crohn's disease	7.78e-06	4.92e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—Crohn's disease	6.81e-06	4.31e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—Crohn's disease	6.01e-06	3.8e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—Crohn's disease	5.26e-06	3.32e-05	CbGpPWpGaD
